A controlled trial of oxypertine in tardive dyskinesia.
A study was undertaken to investigate the effects of oxypertine in treating tardive dyskinesia. The design was double-blind, placebo-controlled, between-patient, in 28 patients from whom previous medication was withdrawn, with 14 patients in each group. Treatment was for 4 weeks. Although more oxypertine patients improved than placebo, i.e. 71.4 vs. 50%, the results did not reach statistically significant difference. A further study is planned to increase the overall number of patients in the study, and to lengthen treatment periods.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D013997:Time Factors
D014150:Antipsychotic Agents; D007211:Indoles; D010879:Piperazines; D004298:Dopamine